Causes of death within 30 days from day 1 of ara-C therapy
| Patient ID . | Age, y . | CR1 duration . | Cytogenetic category . | Adverse event (study day of death) . |
|---|---|---|---|---|
| Laromustine/HDAC, n = 19 | ||||
| 010-004 | 29 | 11.8 | Not available | Multiorgan failure (19); acute respiratory distress (19) |
| 010-008 | 58 | 3.8 | Not available | Grade 3/4 neutropenic sepsis (30); progressive AML (30) |
| 015-001 | 56 | 8.1 | Unfavorable | Diarrhea (9); acute respiratory distress (9) |
| 122-004 | 55 | 9.1 | Unfavorable | Grade 3/4 neutropenic sepsis with pulmonary aspergillosis (17) |
| 001-025 | 49 | 18.6 | Favorable | Pneumonia (25) |
| 121-003 | 38 | 19.5 | Unfavorable | Grade 3/4 neutropenic sepsis (24) |
| 133-002 | 54 | 20.9 | Not available | Grade 3/4 neutropenic sepsis (23) |
| 152-016 | 66 | 11.8 | Intermediate | Cerebral vascular accident (29) |
| 010-003 | 71 | 7.7 | Intermediate | Typhilis (31); grade 3/4 neutropenic sepsis (31) |
| 013-003 | 70 | 6.5 | Intermediate | Sepsis (16) |
| 031-010 | 61 | 7.1 | Unfavorable | Sepsis (23) |
| 033-001 | 68 | 9.6 | Intermediate | Sepsis (30) |
| 129-002 | 80 | 5 | Intermediate | Grade 3/4 neutropenic sepsis (30) |
| 152-008 | 60 | 9.2 | Intermediate | Acute respiratory distress (16) |
| 012-003 | 67 | 6.9 | Intermediate | Septic shock (6) |
| 152-001 | 72 | 11.6 | Intermediate | Grade 3/4 neutropenic sepsis (28) |
| 016-002 | 60 | 13 | Intermediate | Sepsis (20) |
| 094-001 | 73 | 16.4 | Unfavorable | Grade 3/4 neutropenic sepsis with pneumonia (19) |
| 130-005 | 70 | 14 | Intermediate | Grade 3/4 neutropenic sepsis with pneumonia (25) |
| HDAC/placebo, n = 2 | ||||
| 008-012 | 77 | 6.4 | Unfavorable | Supraventricular tachycardia (30) |
| 095-001 | 64 | 9.1 | Unfavorable | AML progression (31) |
| Patient ID . | Age, y . | CR1 duration . | Cytogenetic category . | Adverse event (study day of death) . |
|---|---|---|---|---|
| Laromustine/HDAC, n = 19 | ||||
| 010-004 | 29 | 11.8 | Not available | Multiorgan failure (19); acute respiratory distress (19) |
| 010-008 | 58 | 3.8 | Not available | Grade 3/4 neutropenic sepsis (30); progressive AML (30) |
| 015-001 | 56 | 8.1 | Unfavorable | Diarrhea (9); acute respiratory distress (9) |
| 122-004 | 55 | 9.1 | Unfavorable | Grade 3/4 neutropenic sepsis with pulmonary aspergillosis (17) |
| 001-025 | 49 | 18.6 | Favorable | Pneumonia (25) |
| 121-003 | 38 | 19.5 | Unfavorable | Grade 3/4 neutropenic sepsis (24) |
| 133-002 | 54 | 20.9 | Not available | Grade 3/4 neutropenic sepsis (23) |
| 152-016 | 66 | 11.8 | Intermediate | Cerebral vascular accident (29) |
| 010-003 | 71 | 7.7 | Intermediate | Typhilis (31); grade 3/4 neutropenic sepsis (31) |
| 013-003 | 70 | 6.5 | Intermediate | Sepsis (16) |
| 031-010 | 61 | 7.1 | Unfavorable | Sepsis (23) |
| 033-001 | 68 | 9.6 | Intermediate | Sepsis (30) |
| 129-002 | 80 | 5 | Intermediate | Grade 3/4 neutropenic sepsis (30) |
| 152-008 | 60 | 9.2 | Intermediate | Acute respiratory distress (16) |
| 012-003 | 67 | 6.9 | Intermediate | Septic shock (6) |
| 152-001 | 72 | 11.6 | Intermediate | Grade 3/4 neutropenic sepsis (28) |
| 016-002 | 60 | 13 | Intermediate | Sepsis (20) |
| 094-001 | 73 | 16.4 | Unfavorable | Grade 3/4 neutropenic sepsis with pneumonia (19) |
| 130-005 | 70 | 14 | Intermediate | Grade 3/4 neutropenic sepsis with pneumonia (25) |
| HDAC/placebo, n = 2 | ||||
| 008-012 | 77 | 6.4 | Unfavorable | Supraventricular tachycardia (30) |
| 095-001 | 64 | 9.1 | Unfavorable | AML progression (31) |
HDAC indicates high-dose cytarabine; and AML, acute myelogenous leukemia.